Incyte Corp. | Key People and Executives
Hervé Hoppenot
Chairman, President & Chief Executive Officer
Julian Charles Baker
Lead Independent Director
Jean-Jacques Bienaimé
Independent Director
Wendy L. Dixon
Independent Director
Paul Alan Brooke
Independent Director
Hervé Hoppenot
Chairman, President & Chief Executive Officer
David W. Gryska
Chief Financial Officer & Executive Vice President
Lothar H. Finke
Head-Clinical Development & General Manager-Japan
Steven H. Stein
Chief Medical Officer & Executive Vice President
Reid M. Huber
Chief Scientific Officer & Executive VP
Michael Morrissey
Senior VP & Head-Global Technical Operations
Peter Langmuir
Vice President-Oncology Drug Development
Wenqing Yao
Executive Vice President-Discovery Chemistry
Vijay Iyengar
EVP-Global Strategy & Corporate Development
Paul Trower
Vice President-Finance
Phillip Liu
Associate Director-Applied Technology
Holly Koblish
Associate Director
Barry P. Flannelly
Executive Vice President & General Manager
Keith Mikkelson
Executive Director-Business Development
Kim Solomon
Vice President-Project Management
Robert Newton
Vice President-Drug Discovery Biology
Catalina Loveman
Head-Media Relations
Lauren Kwiecinski
Director-Investor Relations
Michael Charles A. Booth
Vice President-Investor Relations
Paula J. Swain
Executive Vice President-Human Resources
Maria E. Pasquale
Executive Vice President & General Counsel
Julian Charles Baker
Lead Independent Director
Jean-Jacques Bienaimé
Independent Director
Wendy L. Dixon
Independent Director
Paul Alan Brooke
Independent Director
| Address |
1801 Augustine Cut-Off
Wilmington Delaware 19803
United States
|
|
Employees
|
- |
| Website |
http://www.incyte.com |
| Updated |
07/08/2019 |
| Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. |
